Diagnosis and treatment depression in schizophrenia
- PMID: 39006901
- PMCID: PMC11240135
- DOI: 10.17650/2712-7672-2020-1-2-29-42
Diagnosis and treatment depression in schizophrenia
Abstract
Depression is the third most common illness among patients with schizophrenia which negatively affects the course of the disease and significantly contributes to the mortality rate, due to increased suicide. Depression, along with negative symptoms and cognitive deficits, is one of the main factors that significantly decreases the quality of life and the disease prognosis in patients with schizophrenia. In addition, depression increases the frequency of exacerbations and readmissions, decreases the quality and duration of remissions and is associated with more frequent substance abuse and an increased economic burden. Data on the prevalence of depression among patients with schizophrenia are contradictory and are associated with a low detection rate of depression in such patients, a lack of clear diagnostic criteria and difficulties in differentiation between extrapyramidal and negative symptoms. The average prevalence of depression that meets the diagnostic criteria of major depressive episodes in patients with schizophrenia is 25% at a specific point, and 60% over the course of a lifetime; the frequency of subsyndromal depression is much higher. It is essential to distinguish between primary (axial syndrome) and secondary depressive symptoms (extrapyramidal symptoms, psychogenic or nosogenic reactions, social factors, etc.) to determine treatment strategies. The published data relating to randomized clinical trials for the development of evidence-based guidelines are limited. Current recommendations are based mainly on the results of small-scale trials and reviews. Certain atypical antipsychotics (quetiapine, lurasidone, amisulpride, aripiprazole, olanzapine, clozapine) are superior to typical antipsychotics in the reduction of depressive symptoms. Clozapine is effective in the management of patients at risk from suicide. The additional prescription of antidepressants, transcranial magnetic stimulation and electroconvulsive therapy are not always effective and are only possible following the management of acute psychosis in cases when antipsychotic monotherapy proved to be ineffective.
Keywords: antidepressants; antipsychotics; depression; evidence-based therapeutic algorithm; schizophrenia; therapy.
Copyright © 2020, Mosolov S.N.
Conflict of interest statement
This work was carried out with a sponsorship from Angelini Pharma Rus LLC.
Figures
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
-
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315. Turk Psikiyatri Derg. 2022. PMID: 35730516 English, Turkish.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
Cited by
-
The Interrelationship of Benefit Finding, Stigma, and Suicide Risk Among Patients with Schizophrenia and Their Caregivers: A Six-Month Follow-Up Study.Healthcare (Basel). 2024 Oct 31;12(21):2176. doi: 10.3390/healthcare12212176. Healthcare (Basel). 2024. PMID: 39517388 Free PMC article.
-
Biological Methods for Diagnosing Depressive Symptoms in Patients with Schizophrenia: A Narrative Review.Consort Psychiatr. 2024 Sep 26;5(3):31-41. doi: 10.17816/CP15525. eCollection 2024. Consort Psychiatr. 2024. PMID: 39526009 Free PMC article. Review.
-
Efficacy and Safety Profiles of Antipsychotic Drugs as Viewed by Psychiatrists: A Comparative Analysis of Cariprazine and Risperidone.Consort Psychiatr. 2023 Dec 22;4(4):17-27. doi: 10.17816/CP12049. Consort Psychiatr. 2023. PMID: 38618636 Free PMC article.
-
Plasma Neurotrophic Factor Levels are not Associated with the Severity of Depression: Prospective Pilot Study.Consort Psychiatr. 2021 Dec 31;2(4):13-22. doi: 10.17816/CP110. eCollection 2021. Consort Psychiatr. 2021. PMID: 39045452 Free PMC article.
References
-
- Neznanov NG, Martynikhin IA, Mosolov SN. Diagnosis of Schizophrenia in Russia: The Results of a Web-based Survey of Psychiatrists (Part 1. Use of the ICD-10 criteria). Article in Russian Sovremennaia terapiia psikhicheskikh rasstroijstv. 2019;1:2–13. doi: 10.21265/PSYPH.2019.24.24.001. - DOI
Publication types
LinkOut - more resources
Full Text Sources